Key result
This publication is a collection of letters to the editor discussing first-line drugs for hypertension, the Canada Health Act, physician alcohol dependence, and vaccine policies.
Why the study?
Do first-line anti-hypertensive drug classes reduce mortality and cardiovascular events in patients with hypertension compared to placebo or no treatment?
Population
58,040 patients with sustained elevated blood pressure unresponsive to lifestyle measures pooled from 24 RCTs
Comparison
First-line anti-hypertensive drug classes vs Placebo or no treatment
Design
Meta-analysis
Follow-up
at least one year
Authors
Loading...
Low-dose thiazides reduce mortality and events in hypertension; confirms preference over high-dose thiazides and beta-blockers.
Do first-line anti-hypertensive drug classes reduce mortality and cardiovascular events in patients with hypertension compared to placebo or no treatment?
First-line low-dose thiazides effectively reduce all morbidity and mortality outcomes in hypertension, whereas high-dose thiazides and beta-blockers are inferior.
Wright et al. (2009) reported a letter. This publication is a collection of letters to the editor discussing first-line drugs for hypertension, the Canada Health Act, physician alcohol dependence, and vaccine policies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: